Skip to Content

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

The results of KEYNOTE 671 reveal that perioperative chemotherapy with pembrolizumab improves overall survival in resectable non-small-cell lung cancer. Jonathan Spicer presents the study and discusses the concerns regarding patient drop-off in neoadjuvant studies and the positive patient dispositions achieved with this approach.

Jonathan Spicer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top